PARG inhibitory compounds

Patent metadata

Field	Value
Publication number	US-10995073-B2
Application number	US-201916662997-A
Country	US
Kind code	B2
Filing date	Oct 24, 2019
Priority date	Dec 19, 2014
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R 1a , R 1b , R 1c , R 1d , R 1e , W, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

First claim

The invention claimed is:

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the structural formula (II) shown below:

wherein:
R 1a is selected from, fluoro, chloro, cyano, formyl, (1-2C)alkyl, (1-2C) haloalkyl, (2C)alkenyl, and (2C)alkynyl;
R 1b , R 1c , R 1d , and R 1e are each independently selected from H, fluoro and methyl;
X 1 is selected from CR 2 or N; wherein R 2 is H or fluoro;
X 2 is selected from CR 3 or N; wherein R 3 is H or fluoro;
X 3 is selected from CR 4 or N; wherein R 4 is H, halo, cyano, (1-2C)alkyl, (1-2C) haloalkyl, (1-2C)alkoxy, (1-2C)haloalkoxy and (2C)alkynyl; or
R 4 is selected from a group of the formula:
-L 4 −L 4C -Q 4C
wherein
L 4 is absent or (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo;
L 4C is absent or selected from O, S, SO, SO 2 , N(R 4b ), C(O), C(O)O, OC(O), C(O)N(R 4b ), N(R 4b )C(O), N(R 4b )C(O)N(R 4c ), S(O) 2 N(R 4b ), and N(R 4b )SO 2 , wherein R 4b and R 4c are each independently selected from hydrogen and (1-2C)alkyl; and
Q 4C is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heterocyclyl or heteroaryl; and wherein Q 4C is optionally substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, NR 4d R 4e , OR 4d , C(O)R 4d , C(O)OR 4d , OC(O)R 4d , C(O)N(R 4e )R 4d , N(R 4e )C(O)R 4d , S(O) y R 4d (where y is 0, 1 or 2), SO 2 N(R 4e )R 4d , N(R 4e )SO 2 R 4d and (CH 2 ) z NR 4e R 4d (where z is 1, 2 or 3), wherein R 4d and R 4e are each independently selected from H and (1-4C)alkyl;
HET is a fused 5-membered saturated, partially saturated or unsaturated heterocyclic ring of formula:

wherein
bond a is a single bond;
R 5 is H, (1-4C)alkyl or a group of the formula:
-L 1 -L 5 -Q 5
wherein
L 1 is absent or selected from (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo, or a (2-3C)alkenylene or (2-3C)alkynylene linker that is optionally substituted by (1-2C)alkyl;
L 5 is absent or selected from C(O), C(O)O, OC(O), C(O)N(R a ), N(R a )C(O), N(R a )C(O)N(R b ), S(O) 2 N(R a ), and N(R a )SO 2 , wherein R a and R b are each independently selected from hydrogen or (1-2C)alkyl; and
Q 5 is selected from hydrogen, (1-4C)alkyl, aryl, 5-6 membered heteroaryl, (4-6C)cycloalkyl, (4-6C)cycloalkenyl, (2C)alkenyl and 5-6 membered heterocyclyl;
and wherein Q 5 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, amino, cyano, carboxy, carbamoyl, sulphamoyl, trifluoromethoxy, haloalkyl, NR c R d , OR c , C(O)R c , C(O)OR c , OC(O)R c , C(O)N(R c )R d , N(R c )C(O)R d , S(O) y R c (where y is 0, 1 or 2), SO 2 N(R c )R d , N(R c )SO 2 R d or (CH 2 ) z NR c R d (where z is 1, 2 or 3), wherein R c and R d are each independently selected from H or (1-4C)alkyl;
or Q 5 is optionally substituted by a group of the formula;
—W 5 —Y 5 —Z 5
wherein
W 5 is absent or selected from (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo, or a (2-3C)alkenylene or (2-3C)alkynylene linker that is optionally substituted by (1-2C)alkyl;
Y 5 is absent or selected from C(O), C(O)O, OC(O), C(O)N(R e ), N(R e )C(O), N(R e )C(O)N(R f ), S(O) 2 N(R e ), and N(R e )SO 2 , wherein R e and R f are each independently selected from hydrogen and (1-2C)alkyl; and
Z 5 is selected from hydrogen, (1-4C)alkyl, phenyl, 5 or 6-membered heterocyclyl and a 5-6 membered heteroaryl; and wherein Z 5 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl and sulphamoyl;
X 4 is selected from C(═O), C(═NH), C(═S), CHR 6c and N—R 6N ;
wherein
R 6C is selected from hydrogen, cyano, halo and a group of the formula:
-L 6 -L 6C -Q6C
wherein
L 6 is absent or (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo;
L 6C is absent or selected from O, S, SO, SO 2 , N(R g ), C(O), C(O)O, OC(O), C(O)N(R g ), N(R g )C(O), N(R g )C(O)N(R h ), S(O) 2 N(R g ), and N(R g )SO 2 , wherein R g and R h are each independently selected from hydrogen and (1-2C)alkyl; and
Q 6C is hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, NR i R j , OR i , C(O)R i , C(O)OR i , OC(O)R i , C(O)N(R)R i R j , N(R i )C(O)R j , S(O) y R i (where y is 0, 1 or 2), SO 2 N(R i )R j , N(R i )SO 2 R j and (CH 2 ) z NR i R j (where z is 1, 2 or 3), wherein R i and R j are each independently selected from H and (1-4C)alkyl;
R 6N is selected from hydrogen and a group of the formula:
-L 6 -L 6N -Q 6N
wherein
L 6 is absent or (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo;
L 6N is absent or selected from O, S, SO, SO 2 , N(R k ), C(O), C(O)O, OC(O), C(O)N(R k ), N(R k )C(O), N(R k )C(O)N(R l ), S(O) 2 N(R k ) and, or N(R k )SO 2 , wherein R k and R l are each independently selected from hydrogen and (1-2C)alkyl; and
Q 6N is hydrogen, cyano, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, NR m R n , OR m , C(O)R m , C(O)OR m , OC(O)R m , C(O)N(R m )R n , N(R m )C(O)R n , S(O) y R m (where y is 0, 1 or 2), SO 2 N(R m )R n , N(R m )SO 2 R n and (CH 2 ) z NR m R n (where z is 1, 2 or 3), wherein R m and R n are each independently selected from H and (1-4C)alkyl;
X 5 is selected from C(═O), C(═NH), C(═S), CHR 7c and N—R 7N ;
wherein
R 7c is selected from, cyano, halo and a group of the formula:
-L 7 -L 7C -Q 7C
wherein
L 7 is absent or (1-3C)alkylene optionally substituted by (1-2C)alkyl or oxo;
L 7C is absent or selected from O, S, SO, SO 2 , N(R o ), C(O), C(O)O, OC(O), C(O)N(R o ), N(R o )C(O), N(R o )C(O)N(R p ), S(O) 2 N(R o ), and N(R o )SO 2 , wherein R o and R p are each independently selected from hydrogen and (1-2C)alkyl; and
Q 7C is hydrogen, cyano, (1-6C)alkyl, (2C)alkynyl, (2-3C)alkenyl, (3-6C)cycloalkyl, aryl, heterocyclyl or heteroaryl; and wherein Q 7C is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, NR q R r , OR q , C(O)N q , C(O)OR q , OC(O)R q , C(O)N(R q )R r , N(R q )C(O)R r , S(O) y R q (where y is 0, 1 or 2), SO 2 N(R q )R r , N(R q )SO 2 R r or (CH 2 ) z NR q R r , (where z is 1, 2 or 3), wherein R q and R r are each independently selected from H or (1-4C)alkyl; or
Q 7C is optionally substituted by a group of the formula:
-W 7C -L 7′ -Z 7C
wherein
W 7C is absent or (1-3C)alkylene substituted by (1-2C)alkyl or oxo;
L 7 ′ is absent or selected from C(O), C(O)O, OC(O), C(O)N(R s ), N(R s )C(O), N(R s )C(O)N(R t ), S(O) 2 N(R s ), and N(R s )SO 2 , wherein R s and R t are each independently selected from hydrogen or (1-2C)alkyl; and
Z 7

Assignees

• Cancer Research Tech Ltd

Inventors

• Mcgonagle Alison E
• Jordan Allan M
• Waszkowycz Bodhan
• Hutton Colin P
• Waddell Ian D
• Hitchin James R
• Smith Kate M
• Hamilton Niall M

Classifications

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D235/26 Primary

  Oxygen atoms · CPC title

• C07D403/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D417/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title